Navigation Links
Karolinska Development and Uminova Invest Sign Co-operation Agreement
Date:1/14/2010

STOCKHOLM and UMEA, Sweden, January 14 /PRNewswire/ -- Karolinska Development AB and Uminova Invest AB have entered into a co-operation agreement that will enrich the flow of investment opportunities available to Karolinska Development and enable cost effective commercial development for Uminova Invest's portfolio companies. The agreement involves evaluation of potential investments; advise to existing portfolio companies as well as exit issues.

Uminova Invest is a regional private equity capital firm providing capital and competence to prospective growth companies and entrepreneurs with a connection to the Umea University or other educational and research activities in the county of Vasterbotten.

"Umea region excels having created a very strong cluster of life science innovations over the past years and this agreement offers us access to some very exciting commercial opportunities", says Conny Bogentoft, CEO of Karolinska Development.

"Over the past years we have had an ongoing exchange with Karolinska Development, this has now been formalized. This formal co-operation agreement provides further opportunities to create viable companies", says Jan Olsson, CEO of Uminova Invest.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio als
'/>"/>

SOURCE Karolinska Development AB and Uminova Invest AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
2. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
3. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
4. Karolinska Development Closes Fully Subscribed New Share Issue
5. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
8. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
9. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... survive impact by the huge amounts of energy ... energy for photosynthesis. The hypothesis is that the ... the energy throughout the entire protein molecule through ... now managed to successfully ,film, this process. , ... which play a role in photosynthesis and thus ...
(Date:8/27/2014)... 27, 2014 Research and Markets ... Lactic Acid  (Biodegradable Polymer, Food & Beverage, Personal ... to 2019" report to their offering. ... with an asymmetrical carbon atom. The main applications ... food and beverage, personal care product, and pharmaceutical ...
(Date:8/27/2014)... 2014 “We are honored to be ... Ven Thangaraj, CEO of Radiant Sage. “We are offering ... the imaging corelab market to a different level. ... organizations to efficiently and effectively manage the massive amounts ... be analyzed and read by trained physicians. Being recognized ...
(Date:8/27/2014)... 2014 Flagship Biosciences LLC, a leading ... the pharmaceutical and medical device industries, has announced a ... growing company has consolidated its histology and tissue analysis ... Westminster, CO, just north of Denver. The new ... 103rd Ave., Suite 100, Westminster, CO 80021 , Tissue ...
Breaking Biology Technology:DTU researchers film protein quake for the first time 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Flagship Biosciences Announces Relocation and Expansion 2
... (Nasdaq: NPSP ) today reported its financial results ... update on its 2007 milestones and,financial guidance. Update ... partnership with Nycomed to develop,GATTEX(TM) (teduglutide) outside North America, ... corporate milestones for 2007. The company announced that it,has: ...
... Merge Healthcare (Nasdaq: MRGE ; TSX: MRG), today,announced ... NASDAQ,Listing Qualifications Panel stating that the panel determined to ... NASDAQ Stock Market,subject to the Company,s filing of its ... no later than January 29, 2008. As indicated in ...
... Mass., Nov. 1 Proteon Therapeutics,( http://www.proteontherapeutics.com ... first-in-class pharmaceuticals to address the,medical needs of ... presenting,tomorrow at the Annual Meeting of the ... Human Elastase (PRT-201) Dilates Outflow,Veins in a ...
Cached Biology Technology:NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 2NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 3NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 4NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 5NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 6NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 7NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 8NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance 9NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance 2NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance 3Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007 2
(Date:8/27/2014)... available in German . ... most common inherited disease affecting the peripheral nervous system. ... Planck Institute of Experimental Medicine and University Medical Centre ... is impaired in rats with the disease. These cells ... as myelin, which facilitates the rapid transfer of electrical ...
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... advocates, campaigns against trans-fats have largely succeeded in ... aim at sugar for its potential contributions to ... still wrangling over the best way to assuage ... article in Chemical & Engineering News ... Chemical Society. , In the article, Stephen Ritter, ...
Breaking Biology News(10 mins):Potential therapy for incurable Charcot-Marie-Tooth disease 2New study throws into question long-held belief about depression 2
... female hormone estrogen is known to offer protection for the heart, ... New research from the University of California at Merced finds that ... a greater impact on girls, blood pressure than it does on ... between 13 and 17 years old, obese boys were 3.5 times ...
... reached epidemic levels, and pediatricians are on the front ... pre-conference session at 11:30 a.m. Friday, Oct. 14, before ... Exhibition in Boston. The Pediatrics for the ... Innovations in Practice," challenges pediatricians to "step it up ...
... Oct. 11, 2011 Based on its recent analysis ... with the 2011 North American Frost & Sullivan Award ... Biometric Platform™ , - the first scalable, multi-modal biometrics ... iris recognition from a single server. To ...
Cached Biology News:Gender differences in blood pressure appears as early as adolescence 2Pediatricians aim to end childhood obesity within a generation 2Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 2Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 3Frost & Sullivan Recognizes M2SYS for its Path-Breaking Hybrid Biometric Platform(TM) That Offers Unparalleled Flexibility to End-Users 4
... Software enables you to identify over ... can distinguish protein isoforms, protein subsets, ... also visualize peptide-protein associations and relationships ... protein identification and relative protein expression ...
... microscopes offer all of the features of ... Equipped with Koehler illumination, a centerable condenser ... B3 is the workhorse of Motic's range ... the need for re-focusing following a change ...
... Green II RNA gel stain is ... has bright fluorescence when bound to RNA ... ideal for use with either formaldehyde/agarose or ... UV transilluminators. A 500 µL unit size ...
... SYBR Green II RNA gel stain is ... bright fluorescence when bound to RNA and low ... with either formaldehyde/agarose or polyacrylamide gels using laser ... 100 minigels. A 500 µL unit size (S-7564) ...
Biology Products: